Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.
Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback